Espero BioPharma to Present at BIO CEO & Investor conference on February 11, 2019

Jacksonville, FL and Irvine, CA – February 6, 2019 – Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Dr. Lee Golden, Chief Medical Officer, will present at the BIO CEO & Investor Conference on Monday, February 11th, 2019 at 10:30 AM ET. The conference will be held at the New York Marriott Marquis, in New York City.

Dr. Golden will provide a corporate overview and discuss the company’s late-stage product pipeline, including tecarfarin, Espero’s lead product candidate, and anti-arrhythmic drug (AAD) program. Further, he will highlight the Company’s exclusive license agreement with Lee’s Pharmaceutical in China, as well as completion of its Phase 1 study of Tecarfarin in healthy volunteers in Hong Kong.  Tecarfarin has the potential to be the oral anticoagulant therapy of choice for the 3.7 million patients in the United States, and millions more worldwide, who require anticoagulation with a Vitamin K antagonist such as warfarin, including patients with prosthetic heart valves, recurrent deep vein thrombosis or patients with chronic kidney disease, which complicates anticoagulant therapy.

Tecarfarin is a novel Vitamin K antagonist (“VKA”) oral anticoagulant (“OAC”) taken once daily like warfarin that is Phase III ready in the United States.  Tecarfarin is metabolized via tissue esterases, rather than hepatic cytochrome P-450 pathways, which is thought to improve efficacy and safety profile due to more predictable pharmacokinetics and fewer drug-drug interactions. 

About Espero BioPharma, Inc.
Espero BioPharma is a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control. The Company is developing tecarfarin and an anti-arrhythmic program to treat atrial fibrillation (AFib). Tecarfarin and our AAD compounds were designed so that metabolic clearance is not hindered by the body, creating the potential for increased efficacy with a superior safety profile.